**Open Access** 

# Deep Vein Thrombosis: Prevalence and Risk Factors in an Intensive Inpatient Neurorehabilitation Unit

#### Sami Duan\*

Department of Inflammation Immunity, Lerner Research Institute, Cleveland, OH 44195, USA

#### Abstract

Deep Vein Thrombosis (DVT) is a serious medical condition characterized by the formation of Blood Clots (thrombi) within deep veins, most commonly in the legs. These clots can pose significant health risks, particularly in patients undergoing intensive care or rehabilitation following neurological conditions. In the context of an intensive inpatient neurorehabilitation unit, the prevalence of DVT and its associated risk factors become critically important to manage, as these patients often face prolonged periods of immobility and other factors that contribute to thrombotic events. DVT occurs when a blood clot forms in a deep vein, typically in the lower leg, thigh, or pelvis. These clots can block blood flow, causing swelling, pain and potentially life-threatening complications if they break loose and travel to the lungs, causing a Pulmonary Embolism (PE). The incidence of DVT varies across different patient populations, but individuals undergoing intensive neurorehabilitation are at heightened risk due to various factors associated with their condition and treatment protocols.

Keywords: Thrombosis • Blood • Embolism • Pulmonary

#### Introduction

In an intensive inpatient neurorehabilitation setting, the prevalence of DVT can be significant. Patients often experience prolonged periods of bed rest or limited mobility, which are well-established risk factors for DVT. Neurological conditions such as stroke, spinal cord injury, or traumatic brain injury can further exacerbate this risk due to impaired mobility, altered blood flow dynamics and possible systemic inflammation. Studies have indicated that the incidence of DVT among neurorehabilitation patients can range from 7% to 20%, depending on the specific patient population, duration of hospitalization and preventive measures in place. This underscores the importance of vigilant monitoring and proactive management strategies to mitigate the risk of thrombotic events in this vulnerable group. Increased tendency of blood to clot, influenced by factors such as inflammation, medication and underlying medical conditions. Older age, obesity, history of prior thromboembolic events and coexisting medical conditions like diabetes or cardiovascular disease amplify the risk. Diagnosing DVT in neurorehabilitation units can be challenging due to overlapping symptoms with other conditions and limitations in patient mobility for standard diagnostic tests such as Doppler ultrasound. Clinical suspicion and vigilance are crucial, particularly for patients presenting with leg swelling, pain, or localized warmth [1].

To mitigate the risk of DVT in intensive neurorehabilitation units, a multifaceted approach to Encouraging and facilitating early mobilization and physical therapy sessions to improve blood flow and reduce venous stasis. Utilization of graduated compression stockings or intermittent pneumatic compression devices to enhance venous return and reduce clot formation. Consideration of anticoagulant therapy based on individual risk assessment, balancing benefits against potential bleeding risks. Maintaining adequate hydration and nutrition to optimize blood viscosity and overall vascular health. Educating patients and caregivers about the signs and symptoms of DVT, emphasizing the importance of adherence to prescribed preventive measures and early reporting of any concerning symptoms. In cases where DVT is

\*Address for Correspondence: Sami Duan, Department of Inflammation Immunity, Lerner Research Institute, Cleveland, OH 44195, USA; E-mail: SamiDuan500@gmail.com

**Copyright:** © 2024 Duan S. This is an open-access article distributed under the terms of the creative commons attribution license which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

**Received:** 01 June, 2024, Manuscript No. ijn-24-141775; **Editor Assigned:** 04 June, 2024, PreQC No. P-141775; **Reviewed:** 15 June, 2024, QC No. Q-141775; **Revised:** 22 June, 2024, Manuscript No. R-141775; **Published:** 29 June, 2024, DOI: 10.37421/2376-0281.2024.11.569

diagnosed, prompt initiation of treatment is crucial to prevent complications such as PE. Management typically involves anticoagulant therapy to dissolve existing clots and prevent new ones from forming, alongside supportive measures to alleviate symptoms and prevent recurrence [2].

#### **Literature Review**

Deep vein thrombosis represents a significant clinical challenge in intensive inpatient neurorehabilitation units, given the heightened risk factors associated with patient immobility and underlying neurological conditions. Effective management requires a comprehensive understanding of risk factors, diligent monitoring and proactive implementation of preventive strategies. By integrating early mobilization, mechanical and pharmacological prophylaxis and patient education, healthcare teams can significantly reduce the incidence of DVT and improve outcomes for neurorehabilitation patients. Continued research and clinical vigilance are essential to refine protocols and optimize care in this specialized setting, ensuring the safety and well-being of these vulnerable individuals [3-5].

Deep Vein Thrombosis (DVT) poses a significant clinical challenge in the context of intensive inpatient neurorehabilitation units. Understanding its prevalence, associated risk factors, diagnostic challenges, prevention strategies and management is crucial for optimizing patient care and minimizing potentially life-threatening complications.

#### Discussion

Deep vein thrombosis occurs when a blood clot forms within a deep vein, commonly in the legs but potentially in other areas such as the thighs or pelvis. These clots can impede blood flow, leading to symptoms such as swelling, pain and in severe cases, can dislodge and travel to the lungs, causing a Pulmonary Embolism (PE). In neurorehabilitation settings, where patients often experience prolonged periods of immobility and have underlying neurological conditions affecting vascular health, the risk of DVT is heightened. In intensive inpatient neurorehabilitation units, the prevalence of DVT varies but can range significantly due to factors such as patient demographics, duration of hospitalization and the nature of the neurological condition being treated. Studies have reported incidence rates between 7% to 20%, underscoring the importance of vigilance in monitoring and implementing preventive measures. Many patients are immobilized due to neurological deficits, surgeries, or the need for strict bed rest during initial phases of recovery. Reduced muscle pump function and impaired venous return due to limited mobility contribute to stagnant blood flow, promoting clot formation. Neurological conditions such

as strokes or spinal cord injuries can cause damage to blood vessel walls, further increasing the risk of clot formation [6].

## Conclusion

Neurological injuries and accompanying inflammatory responses can elevate the blood's tendency to clot, exacerbating the risk of DVT. Diagnosing DVT in neurorehabilitation units can be complex. Patients may present with symptoms that overlap with their neurological condition, such as leg swelling or pain, which can be mistaken for musculoskeletal issues or neuropathic pain. Moreover, limitations in patient mobility can hinder the use of standard diagnostic tests like Doppler ultrasound. Clinical suspicion and thorough assessment are therefore crucial for timely detection.

## Acknowledgement

None.

## **Conflict of Interest**

None.

#### References

 Konstantinides, Stavros V., Guy Meyer, Cecilia Becattini and Héctor Bueno, et al. "2019 esc guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)." *Eur Heart J* 41 (2020): 543-603.

- Partsch, Hugo and Werner Blättler. "Compression and walking vs. bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin." J Vasc Surg 32 (2000): 861-869.
- Markel, Arie. "Origin and natural history of deep vein thrombosis of the legs." In Sem Vasc Med 5(2005):65-74.
- JCS Joint Working Group. "Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009)–digest version–." Circ J 75 (2011): 1258-1281.
- Janssen, Mirian CH, Hub Wollersheim, Bert Verbruggen and Irena RO Nováková. "Rapid D-dimer assays to exclude deep venous thrombosis and pulmonary embolism: Current status and new developments." Semin Thromb Hemostas 24 (1998) 393-400.
- Simonneau, G, S. Laporte, P. Mismetti and A. Derlon, et al. "A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer." J Thromb Haemost 4 (2006): 1693-1700.

How to cite this article: Duan, Sami. "Deep Vein Thrombosis: Prevalence and Risk Factors in an Intensive Inpatient Neurorehabilitation Unit." *Int J Neurorehabilitation Eng* 11 (2024): 569.